Macular Degeneration Trial, Recruiting NCT03848663 Sponsor: University of Minnesota Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT03848663
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 16 years of age or older.
  • People who have lost central vision in both eyes, where the area of vision loss is at least 5 degrees wide and includes the central focal point of vision.
  • People whose eyes hold a steady, consistent gaze within a very small range (within plus or minus 1 degree) using the part of their vision they rely on most.
  • People who show no signs of cognitive (thinking or memory) difficulties, as measured by a standard assessment called the Mini-Mental State Examination.
  • People whose eyes can be successfully tracked by the eye-tracking equipment used in the trial.

Who may not be able to join:

  • People whose central vision loss is smaller than 5 degrees wide, does not include the central focal point of vision, or only affects one eye.
  • People whose gaze is not steady enough, meaning their eye position varies by more than plus or minus 1 degree when using their remaining vision.
  • People who show signs of cognitive (thinking or memory) difficulties based on the Mini-Mental State Examination.
  • People whose eyes cannot be successfully tracked by the eye-tracking equipment used in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stephen Engel, Ph.D., University of Minnesota

Phone: 612-625-5571

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 February 2022
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Reading Speed for Individual Words; Reading Speed for Sentences; Reading Speed for Natural Text Samples; Reading error rate for Individual Words; Reading error rate for Sentences; Reading error rate for Natural Text Samples

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov